A preliminary investigation of the enzymatic inhibition of 5α-reductase and growth of prostatic carcinoma cell line LNCap-FGC and by natural astaxanthin and Saw Palmetto lipid extract in vitro

Journal of Herbal Pharmacotherapy

Volumn 5, Issue 1, 2005, Pages 17-26

  Anderson, Mark L ^a  

^a Triarco Industries Inc   (United States)

Author keywords

Astaxanthin; Prostate; Saw Palmetto

Indexed keywords

ALPHASTAT; ASTAXANTHIN; CAROTENOID; PLANT MEDICINAL PRODUCT; SABAL EXTRACT; SAW PALMETTO LIPID EXTRACT; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; HERBAL MEDICINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; RAT; SABAL; SYMPTOMATOLOGY;

ANDROGEN ANTAGONISTS; BETA CAROTENE; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SERENOA; TESTOSTERONE 5-ALPHA-REDUCTASE; XANTHOPHYLLS;

EID: 27544499021     PISSN: 15228940     EISSN: None     Source Type: Journal    
DOI: 10.1300/J157v05n01_03     Document Type: Article

References (14)

1. Bone K. Saw Palmetto. A Critical Review. European J Herbal Med 4:15-24, 1999.
2. Cote RJ, Skinner EC, Salem CE. The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels. British J of Cancer 78:423-418, 1998.
3. Delos S, Iehle C, Martin PM. Inhibition of the activity of basic 5α-reductase (type I) detected in DU 145 cells and expressed in insect cells. J Steroid Biochem. Molec. Biol. 48:247-352, 1994.
4. Iehle C, Delos S, Guirou O. Human prostatic steroid 5α-reductase isoforms - A comparative Study of Selective Inhibitors. J Steroid Biochem. Molec. Biol. 54:273-279, 1995.
5. Carraro JC, Raynaud JP, Koch G, Comparison of phytotherapy (permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients. The Prostate 29:231-240, 1996.
6. Shaneyfelt T, Husein R, Bubley G. Hormonal predictors of prostate cancer: A meta-analysis. J Clin. Oncol. 18:847-853, 2000.
7. Weisburger JH. International symposium on lycopene and tomato products in disease prevention: An Introduction. Proc. Exp. Bio. Med., 218, 299-306, 1998.
8. Ohno Y, Yoshida O, Oishi K. Dietary beta-carotene and cancer of the prostate: A case control study in Kyoto, Japan. Cancer Res. 48, 1331-1336, 1988.
9. Chew B, Park J, Wong M. A comparison of the anticancer activities of dietary beta-carotene, canthaxanthin and astaxanthin in mice in vivo. Anticancer Research 19, 1849-1854, 1999.
10. Woodall AG, Britton G, Jackson M. Carotenoids and protection of phospholipids in solution or in liposomes against oxidation by peroxyl radicals: Relationship between carotenoid structure and protective ability. Biochim. Biophys. Acta. 1336, 575-586, 1997.
11. Milon A, Wolff G, Nakatani Y. Organic carotenoid-phospholipid bilayer systems. Incorporation of zeaxanthin, astaxanthin and their C50 homologous dimyristoylphosphatidylcholine vesicles. Helv. Chemica. 69, 12-24, 1986.
12. Tanaka T, Morishita Y, Suzui M. Chemoprevention of mouse urinary bladder carcinogenesis by the naturally occurring carotenoid astaxanthin. Carcinogenesis 15, 15-19, 1994.
13. Tanaka T, Kawamori T, Ohnishi M. Suppression of azomethane-induced rat colon carcinogenesis by dietary administration of naturally occurring xanthophylls astaxanthin and canastaxanthin during the postinitiation phase. Carcinogenesis 16, 2957-2963, 1995.
14. Tanaka T, Makita H, Ohnishi M. Chemoprevention of rat oral carcinogenesis by naturally occurring xanthophylls astaxanthin and canastaxanthin. Cancer Res. 55, 4059-4064, 1995.